Connors Investor Services Inc. decreased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 5.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,526 shares of the company’s stock after selling 3,610 shares during the period. Connors Investor Services Inc. owned 0.18% of Omnicell worth $2,974,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in OMCL. Carillon Tower Advisers Inc. bought a new stake in Omnicell during the 4th quarter valued at $38,612,000. Rockefeller Capital Management L.P. bought a new stake in Omnicell during the 1st quarter valued at $20,250,000. Eagle Asset Management Inc. raised its stake in Omnicell by 36.8% during the 4th quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after acquiring an additional 367,687 shares in the last quarter. Kennedy Capital Management Inc. raised its stake in Omnicell by 199.2% during the 4th quarter. Kennedy Capital Management Inc. now owns 465,483 shares of the company’s stock valued at $22,576,000 after acquiring an additional 309,913 shares in the last quarter. Finally, Braun Stacey Associates Inc. bought a new stake in Omnicell during the 4th quarter valued at $9,391,000. 98.00% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Robin Gene Seim sold 13,286 shares of the business’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $46.48, for a total value of $617,533.28. Following the sale, the insider now owns 74,121 shares of the company’s stock, valued at approximately $3,445,144.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary S. Petersmeyer sold 1,650 shares of the business’s stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $46.13, for a total value of $76,114.50. The disclosure for this sale can be found here. Insiders sold a total of 39,161 shares of company stock worth $1,786,193 in the last three months. Company insiders own 3.71% of the company’s stock.
OMCL opened at $45.65 on Friday. Omnicell, Inc. has a one year low of $39.75 and a one year high of $55.40. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.22 and a current ratio of 1.68. The firm has a market capitalization of $1.78 billion, a PE ratio of 253.61, a PEG ratio of 2.11 and a beta of 0.76.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, April 26th. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.04. Omnicell had a return on equity of 4.11% and a net margin of 4.55%. The company had revenue of $182.60 million for the quarter, compared to the consensus estimate of $177.49 million. During the same quarter in the previous year, the business earned $0.06 EPS. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. research analysts forecast that Omnicell, Inc. will post 1.38 EPS for the current year.
Several analysts have weighed in on OMCL shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 target price on shares of Omnicell in a research note on Tuesday, April 3rd. BidaskClub raised Omnicell from a “sell” rating to a “hold” rating in a research note on Saturday, April 7th. Piper Jaffray Companies lifted their target price on Omnicell from $38.00 to $44.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. Oppenheimer reaffirmed a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Monday, January 29th. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $56.67.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.